Investor Presentaiton

Dermatology Pipeline for Unmet Medical Needs ONENESS Product Target Category Patent Indication Discovery/ Pre- clinical Phase 1 Phase 2 Phase 3 Regulatory submission 4 Taiwan FESPIXON (ON1011) M1/M2 Botanical Global Diabetic Foot Ulcer CN, SG, MY US FB825 2 CεmX mAb Global with LEO Pharma Atopic Dermatitis (AD) US Allergic Asthma (AA) Taiwan, US IND Neutrophilic Taiwan, US IND Asthma FB704A IL-6 mAb Global Chronic Kidney Disease Hepatocellular OB318 Multiple NCE Global Taiwan, US IND carcinoma³ SNS812 Virus Nucleic Acid Global with MBS COV-Flu Infection Immunology Key milestones 2022: China NDA 2023: Complete US PIII trial enrollment 2022: Complete Phase Ila study in AD; 2023: Complete Phase Ila study in AA 2023: Complete Phase II trial 2023: Complete Phase I study 1 ON101 has been completed a Phase 3 clinical trial and is undergoing another one (one for China and Taiwan registration, the other for U.S. registration). Drug approval has been obtained in Taiwan. NDA submitted to the NMPA and health authorities in South East Asia.. ON101 can potentially be used for treatment of venous leg ulcers and pressure ulcers in the future. 12 China right has been licensed to Microbio Shanghai and worldwide exclusive license jointly licensed with Micorbio Shanghiai to LEO Pharma | 3 Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer | 4 Regulatory submission includes NDA submission and Pre-NDA submission. | AD: atopic dermatitis; AA: allergic asthma 2022: File IND | 7

View entire presentation